AstraZeneca Signs an Agreement with Emergent BioSolutions to Expand Manufacturing of AZD1222 for COVID-19

 AstraZeneca Signs an Agreement with Emergent BioSolutions to Expand Manufacturing of AZD1222 for COVID-19

AstraZeneca Signs an Agreement with Emergent BioSolutions to Expand Manufacturing of AZD1222 for COVID-19

Shots:

  • Emergent will provide CDMO services for AstraZeneca’ AZD1222. The agreement valued ~174M through 2021 and follows an $87M agreement signed in June for development services, performance and process qualification, raw materials, and an initial capacity reservation
  • The two companies may enter additional commercial manufacturing agreement as the candidate progresses over three years through Emergent’s flexible capacity deployment model. The agreement follows CDMO partnership b/w Emergent and the BARDA signed in June to pave the way for OWS high-priority innovators
  • The University of Oxford and its spin-out company, Vaccitech co-invented AZD1222 and was licensed to AstraZeneca. The vaccine is under clinical trial for COVID-19

Click here ­to­ read full press release/ article | Ref: Emergent | Image: PharmaShots

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post